BBT-001

N/A

Report date: 2026/04/14 14:44:09

Base Information

Drug NameBBT-001
Drug Alias NameBBT001BBT-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-31 modulatorsInterleukin-4 receptor subunit alpha modulators
TargetsInterleukin-31Interleukin-4 receptor subunit alpha
Therapy Area/IndicationsChronic UrticariaDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBambusa Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanzhuyao (Beijing) Biomedical Technology Co LtdBambusa Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsChronic UrticariaDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A